Found: 10
Select item for more details and to access through your institution.
Role of Ritonavir in the Drug Interactions Between Telaprevir and Ritonavir-Boosted Atazanavir.
- Published in:
- Clinical Infectious Diseases, 2014, v. 58, n. 2, p. 268, doi. 10.1093/cid/cit693
- By:
- Publication type:
- Article
Risk of Liver Decompensation Among HIV/Hepatitis C Virus–Coinfected Individuals With Advanced Fibrosis: Implications for the Timing of Therapy.
- Published in:
- Clinical Infectious Diseases, 2013, v. 57, n. 10, p. 1401, doi. 10.1093/cid/cit537
- By:
- Publication type:
- Article
Benefits From Sustained Virologic Response to Pegylated Interferon Plus Ribavirin in HIV/Hepatitis C Virus–Coinfected Patients With Compensated Cirrhosis.
- Published in:
- Clinical Infectious Diseases, 2013, v. 56, n. 11, p. 1646
- By:
- Publication type:
- Article
Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2012, v. 67, n. 3, p. 681, doi. 10.1093/jac/dkr534
- By:
- Publication type:
- Article
Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2011, v. 66, n. 11, p. 2605
- By:
- Publication type:
- Article
Liver Fibrosis, Host Genetic and Hepatitis C Virus Related Parameters as Predictive Factors of Response to Therapy against Hepatitis C Virus in HIV/HCV Coinfected Patients.
- Published in:
- PLoS ONE, 2014, v. 9, n. 7, p. 1, doi. 10.1371/journal.pone.0101760
- By:
- Publication type:
- Article
HCV Viral Decline at Week 2 of Peg-IFN-Alpha-2a/RBV Therapy as a Predictive Tool for Tailoring Treatment in HIV/HCV Genotype 1 Co-Infected Patients.
- Published in:
- PLoS ONE, 2014, v. 9, n. 6, p. 1, doi. 10.1371/journal.pone.0099468
- By:
- Publication type:
- Article
Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients.
- Published in:
- PLoS ONE, 2012, v. 7, n. 11, p. 1, doi. 10.1371/journal.pone.0048959
- By:
- Publication type:
- Article
Influence of IL28B Polymorphisms on Response to a Lower-Than-Standard Dose peg-IFN-α 2a for Genotype 3 Chronic Hepatitis C in HIV-Coinfected Patients.
- Published in:
- PLoS ONE, 2012, v. 7, n. 1, p. 1, doi. 10.1371/journal.pone.0028115
- By:
- Publication type:
- Article
CD4+ T cell restoration and control of hepatitis C virus replication after childbirth.
- Published in:
- 2020
- By:
- Publication type:
- journal article